Panels include Structuring Your Life Sciences Transaction - Licensing vs. M&A vs. Asset Sale and Key Issues for Your Biopharma Licensing Deal - IP, Scientific, and More

Learning Outcomes:

• Deal trends
• Considerations when structuring your deal
• Should you do an M&A vs. license vs. asset sale – considerations for deal
• Strategies for doing a deal with big pharma
• What does big pharma look for in a deal structure?
• Is licensing a way to an M&A deal with big pharma?
• Key non-economic issues for your biopharma licensing deal
• IP – how does big pharma diligence it, and how can a biotech satisfy a big pharma
• Scientific rigor – How does a big pharma evaluate your science?
• How do these key issues play into your license agreement?
• How do you run an efficient and productive diligence process?
• How should you time your licensing deal with your data readout?